Accéder au contenu
Merck

Cystatin C loaded in brain-derived extracellular vesicles rescues synapses after ischemic insult in vitro and in vivo.

Cellular and molecular life sciences : CMLS (2024-05-21)
Yuqi Gui, Yohan Kim, Santra Brenna, Maximilian Wilmes, Giorgio Zaghen, Chris N Goulbourne, Lennart Kuchenbecker-Pöls, Bente Siebels, Hannah Voß, Antonia Gocke, Hartmut Schlüter, Michaela Schweizer, Hermann C Altmeppen, Tim Magnus, Efrat Levy, Berta Puig
RÉSUMÉ

Synaptic loss is an early event in the penumbra area after an ischemic stroke. Promoting synaptic preservation in this area would likely improve functional neurological recovery. We aimed to detect proteins involved in endogenous protection mechanisms of synapses in the penumbra after stroke and to analyse potential beneficial effects of these candidates for a prospective stroke treatment. For this, we performed Liquid Chromatography coupled to Mass Spectrometry (LC-MS)-based proteomics of synaptosomes isolated from the ipsilateral hemispheres of mice subjected to experimental stroke at different time points (24 h, 4 and 7 days) and compared them to sham-operated mice. Proteomic analyses indicated that, among the differentially expressed proteins between the two groups, cystatin C (CysC) was significantly increased at 24 h and 4 days following stroke, before returning to steady-state levels at 7 days, thus indicating a potential transient and intrinsic rescue mechanism attempt of neurons. When CysC was applied to primary neuronal cultures subjected to an in vitro model of ischemic damage, this treatment significantly improved the preservation of synaptic structures. Notably, similar effects were observed when CysC was loaded into brain-derived extracellular vesicles (BDEVs). Finally, when CysC contained in BDEVs was administered intracerebroventricularly to stroked mice, it significantly increased the expression of synaptic markers such as SNAP25, Homer-1, and NCAM in the penumbra area compared to the group supplied with empty BDEVs. Thus, we show that CysC-loaded BDEVs promote synaptic protection after ischemic damage in vitro and in vivo, opening the possibility of a therapeutic use in stroke patients.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps anti-NeuN, from chicken, purified by affinity chromatography
Sigma-Aldrich
Anticorps anti-PSD95, clone K28/43, clone K28/43, from mouse
Sigma-Aldrich
Anti-Histone H1° Antibody, clone 34, clone 34, from mouse